Abbott Trials Absorb™ Bioresorbable Vascular Scaffold Against Metallic Drug Eluting Stent

Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company’s XIENCE PRIME™ Everolimus Eluting Coronary Stent System.

Most read

Latest

^